Current Zika status and what ‘still a thing’ means
Zika is still a thing, but the pattern of risk has shifted from explosive outbreaks to persistent, lower-level transmission with periodic waves. Once concentrated in the 2015–2016 era in the Americas, the virus remains present in many tropical and subtropical regions, driven mainly by mosquito-borne spread and sustained by sexual transmission and travel-related importations. Large, widespread epidemics are less common, yet Zika continues to affect pregnant people and families where Aedes mosquitoes bite and where health systems may lack routine testing or counseling. Understanding today’s risk requires looking at where the virus circulates, how it spreads, how often it is tested, and what long-term outcomes are documented.
What Zika is and how it behaves
Basic virology and ecology
Zika virus is a flavivirus primarily transmitted by Aedes mosquitoes, especially Aedes aegypti and Ae. albopictus, the same day-biting mosquitoes that also spread dengue and chikungunya. After a mosquito bite, the virus can be found in blood, body fluids, and tissues. Two notable features distinguish Zika from some other arboviruses: it can cross the placenta and infect fetal brain tissue, and it can be transmitted sexually from an infected person to partners through semen, vaginal fluids, and other routes. These properties create layered transmission patterns that persist even when mosquito numbers dip seasonally.
Patterns of human infection and immunity
Most Zika infections are asymptomatic or cause only mild signs such as fever, rash, conjunctivitis, muscle and joint pain, headache, and nonpruritic rash, typically lasting several days to a week. Infection generally confers some degree of future immunity, but the durability and breadth of that protection are not fully characterized. Because many people never seek testing, the true infection burden is uncertain. In areas with previous outbreak waves, population-level seroprevalence varies widely by age, neighborhood, and vector control intensity, shaping residual but uneven community risk.
Where Zika continues to circulate
Endemic regions and hot spots
Zika is now considered endemic in many parts of Latin America and the Caribbean, sub-Saharan Africa, parts of South and Southeast Asia, and some Pacific islands. Within countries, risk is not uniform; urban and peri-urban areas with dense Aedes populations, irregular water storage, and limited vector control can sustain transmission. Outbreaks often follow periods of heavy rainfall, El Niño-related warming, or disrupted sanitation, which expand mosquito breeding sites. Because many places do not conduct systematic surveillance, reported case counts usually underestimate true incidence and the timing of waves.
Imported cases and travel-related risk
Travel-associated cases remain a consistent source of local reinitiation in regions where Aedes mosquitoes are present. International visitors who acquire infection abroad can be bitten shortly after return by local mosquitoes, potentially seeding onward transmission if competent vectors and environmental conditions align. This dynamic keeps Zika relevant for clinicians in nonendemic countries and for travelers who may need guidance before, during, and after trips to risk areas. Air travel and regional mobility also mean that Zika risk can pulse quickly after increases in nearby transmission.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Continued geographic presence | Endemic in multiple countries across the Americas, Africa, Asia, and Pacific islands with periodic local outbreaks | WHO, CDC, PAHO surveillance summaries |
| Primary transmission route today | Mosquito-borne by day-biting Aedes species, with additional sexual and congenital routes | Peer-reviewed arbovirus reviews and outbreak investigations |
| Pregnancy-related risk | Zika can cause congenital Zika syndrome, including microcephaly and other neurodevelopmental conditions | Case series, prospective cohort studies |
| Testing approach | RT-PCR in acute serum and urine up to several days after symptom onset; serology with plaque reduction neutralization test to clarify recent versus past infection | Public health laboratory guidance |
| Estimate of people living with long-term consequences | Continual rather than large acute waves; sequelae concentrated among infants of infected pregnancies and individuals with severe initial illness | Ongoing cohort and surveillance data |
How Zika spreads and who is at risk
Mosquito-borne transmission dynamics
Daytime-biting Aedes mosquitoes are the primary bridge vectors. When a mosquito feeds on a person with Zika in their blood, the virus can disseminate to salivary glands and be passed to new hosts during subsequent blood meals. Outbreak potential depends on mosquito density, human density, viral importation, and environmental conditions that favor mosquito survival and biting frequency. Even after the visible peak of an outbreak, low-level transmission can continue in neighborhoods where vector control is inconsistent or stagnant water habitats persist.
Sexual and congenital transmission
Zika has been isolated from semen, vaginal fluids, cervical secretions, and urine, and documented sexual transmission has occurred from male and female partners. The virus can persist in semen for weeks to months, longer than in blood or other fluids. This prolongs risk after symptom resolution and underscores the importance of safer sex or consistent condom use during and after potential exposure. For pregnant people, fetal infection can occur at any stage of pregnancy and can lead to a range of birth outcomes, including congenital Zika syndrome and pregnancy loss.
Testing, diagnosis, and clinical guidance
When and what to test for
In symptomatic patients with compatible illness and relevant exposure, RT-PCR can detect viral RNA in serum and urine during the first week of illness; after this window, serologic testing, ideally with plaque reduction neutralization tests, helps differentiate recent Zika infection from other flaviviruses. For pregnant people with possible exposure, guidance emphasizes both symptom-based and ongoing risk-based testing, often coordinated with obstetric care and public health authorities. Timing of tests and interpretation must account with recent vaccination or other flavivirus infections that may complicate serology.
Interpreting results and follow-up
A positive PCR result confirms recent infection, while serology may require follow-up and additional testing to pinpoint timing. For pregnancies, ultrasound and, when indicated, fetal MRI, amniocentesis with Zika testing, and detailed anatomy scans can help assess potential effects. Decisions about pregnancy management should be made together with clinicians and public health experts, balancing current evidence, local transmission patterns, and individual circumstances.
Pregnancy outcomes and long-term health concerns
Congenital Zika syndrome and neurodevelopmental follow-up
Prenatal Zika infection is strongly associated with congenital Zika syndrome, which includes severe microcephaly, brain anomalies, eye defects, hearing loss, and joint contractures. Not all infected pregnancies lead to these outcomes, and the range of effects can vary widely. Infants with possible congenital exposure should have comprehensive evaluations, including neurodevelopmental monitoring, ophthalmology and audiology assessments, and early intervention services when needed. Families benefit from coordinated care networks that address medical, developmental, and psychosocial needs over time.
Guillain-Barré syndrome and other complications
Among adults and older children, Zika has been linked to an increased risk of Guillain-Barré syndrome and other neurologic complications such as meningoencephalitis. While these events are relatively rare on a population level, they underscore that Zika is not a mild illness for everyone. People with substantial symptoms or neurologic changes should seek medical care and discuss appropriate evaluation and supportive management.
Prevention and community-level strategies
Vector control and personal protection
Reducing Aedes mosquito populations and limiting bites are the cornerstones of Zika prevention. Key measures include eliminating standing water, using screens and bed nets where appropriate, applying EPA-registered insect repellents, wearing light-colored long sleeves and pants, and promoting community-wide vector control when needed. Integrated approaches that combine source reduction, biological controls, and public education are more effective than any single tactic alone. These measures also reduce risk of other mosquito-borne diseases such as dengue and chikungunya, which often circulate in similar settings.
Travel guidance and risk communication
Pre-travel planning should include up-to-date information on local Zika activity, consultation with healthcare providers, and discussion of family planning considerations. For people who are pregnant or planning pregnancy, clinicians may advise postponing travel to areas with ongoing risk and reinforcing bite avoidance. Clear communication, accessible summaries, and multilingual materials help travelers make informed decisions and use prevention methods consistently. After travel, guidance on testing and symptom monitoring supports early recognition and reduces possible onward transmission.
Looking ahead: surveillance and research priorities
Sustained Zika activity underscores the need for robust surveillance, improved diagnostics, and better understanding of long-term outcomes. Research priorities include characterizing population immunity, evaluating vaccine candidates, and refining guidance for pregnant people and families. Integrated programs that address Aedes mosquitoes alongside other arboviruses can strengthen public health infrastructure and improve responses to future threats. For clinicians and public health professionals, maintaining awareness of Zika ensures timely testing, counseling, and coordinated care for affected pregnancies.